Advertisement

Mifepristone: ten years later

  • Author Footnotes
    1 Formerly affiliated with Department of Family Medicine, University at Buffalo, Buffalo, NY, USA.
    Eric A. Schaff
    Correspondence
    Tel.: +1 585 233 2124; fax: +1 866 585 0371.
    Footnotes
    1 Formerly affiliated with Department of Family Medicine, University at Buffalo, Buffalo, NY, USA.
    Affiliations
    Director of Adolescent Medicine, Department of Pediatrics, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Search for articles by this author
  • Author Footnotes
    1 Formerly affiliated with Department of Family Medicine, University at Buffalo, Buffalo, NY, USA.

      Abstract

      While pregnant women have sought abortifacients for thousands of years, they had no success at finding one that both worked and did not jeopardize their lives in the process. The discovery of mifepristone, with both anti-glucocorticoid and anti-progesterone properties, has had a profound effect on women's lives while weaving the abortion-related political hazards. Despite the controversies, millions of women around the world have used mifepristone for medical abortion. This review describes how researchers addressed the numerous barriers of a mifepristone abortion (i.e., gestational age limitation, lengthy process, high costs, complex regimen, failures, side effects and complications) and continue to improve upon the limited numbers and types of clinicians offering mifepristone.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. http://www.who.int/reproductivehealth/topics/unsafe_abortion/hrpwork/en/index.html [accessed June 18, 2009].

        • Singh S.
        Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries.
        Lancet. 2006; 368: 1887-1892
        • Bartlett L.A.
        • Berg C.J.
        • Shulman H.B.
        • et al.
        Risk factors for legal induced abortion-related mortality in the United States.
        Obstet Gynecol. 2004; 103: 729-737
        • Jones R.K.
        • Zolna M.R.
        • Henshaw S.K.
        • Finer L.B.
        Abortion in the United States: incidence and access to services, 2005.
        Perspect Sexual Repro Health. 2008; 40: 6-16
        • Jones R.J.
        • Henshaw S.K.
        Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden.
        Perspect Sexual Repro Health. 2002; 34: 154-161
      2. WHO. Essential Medicines, WHO Model List 20 (14th edition, revised March 2005) at http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf [accessed May 17, 2009].

        • Birgerson L.
        • Odlind V.
        Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane.
        Fertil Steril. 1987; 48: 565-570
        • Creinin M.D.
        • Vittinghoff E.
        • Keder L.
        • Darney P.D.
        • Tiller G.
        Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy.
        Contraception. 1996; 53: 321-327
        • Wiebe E.
        • Dunn S.
        • Guilbert E.
        • Jacot F.
        • Lugtig L.
        Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.
        Obstet Gynecol. 2002; 99: 813-819
        • Creinin M.D.
        • Vittinghoff E.
        Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial.
        JAMA. 1994; 272: 1190-1195
        • Schaff E.A.
        • Eisinger S.H.
        • Franks P.
        • Kim S.S.
        Methotrexate and misoprostol for early abortion.
        Fam Med. 1996; 28: 198-203
        • Spitz I.M.
        • Bardin C.W.
        • Benton L.
        • Robbins A.
        Early pregnancy termination with mifepristone and misoprostol in the United States.
        NEJM. 1998; 338: 1241-1247
        • Ashok P.W.
        • Penney G.C.
        • Flett G.M.
        • Templeton A.
        An effective regimen for early medical abortion: a report of 2000 consecutive cases.
        Hum Reprod. 1998; 13: 2962-2965
        • Zieman M.
        • Fong S.K.
        • Benowitz N.L.
        • Banskter D.
        • Darney P.D.
        Absorption kinetics of misoprostol with oral or vaginal administration.
        Obstet Gynecol. 1997; 90: 88-92
        • Middleton T.
        • Schaff E.
        • Fielding S.L.
        • et al.
        Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
        Contraception. 2005; 72: 328-332
      3. http://www.acog.org/publications/patient_education/bp043.cfm [accessed June 18, 2009].

      4. http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=12522&nbr=6446 [accessed June 18, 2009].

      5. http://www.rcog.org.uk/womens-health/clinical-guidance/about-abortion-care-what-you-need-know [accessed June 18, 2009].

      6. http://whqlibdoc.who.int/publications/2006/9241594845_eng.pdf [accessed June 18, 2009].

      7. http://codes.ohio.gov/orc/2919.123 [accessed June 14, 2009].

      8. http://en.wikipedia.org/wiki/Off-label_use [accessed September 20, 2009].

      9. http://www.earlyoptionpill.com/section/health_professionals/providing_mifeprex and http://www.earlyoptionpill.com/userfiles/file/MedicationGuide071905.pdf [accessed September 20, 2009].

        • Holmgren K.
        Women's evaluation of three early abortion methods.
        Acta Obstet Gynecol Scand. 1992; 71: 616-623
        • Schaff E.A.
        • Fielding S.L.
        • Westhoff C.
        • et al.
        Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial.
        JAMA. 2000; 284: 1948-1953
        • Creinin M.D.
        • Fox M.C.
        • Teal S.
        • Chen A.
        • Schaff E.A.
        • Meyn L.A.
        • et al.
        A randomized comparison of misoprostol 6���8 hours versus 24 hours after mifepristone for abortion.
        Obstet Gynecol. 2004; 103: 851-859
        • Creinin M.D.
        • Schreiber C.A.
        • Bednarek P.
        • Lintu H.
        • Wagner M.S.
        • Meyn L.A.
        • et al.
        Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial.
        Obstet Gynecol. 2007; 109: 885-894
        • el-Refaey H.
        • Rajasekar D.
        • Abdalla M.
        • Calder L.
        • Templeton A.
        Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
        NEJM. 1995; 332: 983-987
        • Clark W.
        • Panton T.
        • Hann L.
        • Gold M.
        Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated.
        Contraception. 2007; 75: 131-135
        • Winikoff B.
        • Sivin I.
        • Coyaji K.J.
        • et al.
        Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone���misoprostol versus surgical abortion.
        Am J Obstet Gynecol. 1997; 176: 431-437
        • Elul B.
        • Hajri S.
        • Ngoc N.N.
        • et al.
        Can women in less-developed countries use a simplified medical abortion regimen.
        Lancet. 2001; 357: 1402-1405
      10. Wu S. Medical abortion in China. J Am Med Womens Assoc 2004;55(3 Suppl):197--179, 204.

        • Parashar P.
        • Iversen O.E.
        • Midboe G.
        • Myking O.
        • Bjorge L.
        Medical abortion in the first trimester: the use of serum hCG and endometrial thickness as markers of completeness.
        Eur J Contracept Reprod Health Care. 2007; 12: 366-371
        • Marrs R.P.
        • Kletzky O.A.
        • Howard W.F.
        • Mishell Jr, D.R.
        Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion.
        Am J Obstet Gynecol. 1979; 135: 731-736
        • Godfrey E.M.
        • Anderson A.
        • Fielding S.L.
        • Meyn L.
        • Creinin M.D.
        Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited.
        Contraception. 2007; 75: 378-382
        • Clark W.H.
        • Gold M.
        • Grossman D.
        • Winikoff B.
        Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research.
        Contraception. 2007; 75: 245-250
        • WHO Task Force on Post-ovulatory Methods of Fertility Regulation
        Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial.
        Br J Obstet Gynaecol. 2000; 107: 524-530
        • Kapp N.
        • Borgatta L.
        • Ellis S.C.
        • Stubblefield P.
        Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion.
        Contraception. 2006; 73: 525-527
        • Liao A.H.
        • Han X.J.
        • Wu S.Y.
        • Xiao D.Z.h.
        • Xiong C.L.
        • Wu X.R.
        Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion.
        Eur J Obstet Gynecol Reprod Biology. 2004; 116: 211-216
        • World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation
        Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial.
        BJOG. 2001; 108: 738-742
        • Ho P.C.
        • Ngai S.W.
        • Liu K.L.
        • Wong G.C.
        • Lee S.W.
        Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy.
        Obstet Gynecol. 1997; 90: 735-738
        • Arvidsson C.
        • Hellborg M.
        • Gemzell-Danielsson K.
        Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.
        Eur J Obstet Gynecol Reprod Biol. 2005; 123: 87-91
        • Tang O.S.
        • Chan C.C.
        • Ng E.H.
        • Lee S.W.
        • Ho P.C.
        A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation.
        Hum Reprod. 2003; 18: 2315-2318
        • Henderson J.
        • Hwang A.
        • Harper C.
        • Stewart F.
        Safety of mifepristone abortions in clinical use.
        Contraception. 2005; 72: 175-178
        • Kawonga M.
        • Blanchard K.
        • Cooper D.
        • Cullingworth L.
        • Dickson K.
        • Harrison T.
        • et al.
        Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa.
        J Fam Plann Reprod Health Care. 2008; 34: 159-164
        • Coyaji K.
        Early medical abortion in India: three studies and their implications for abortion services.
        J Am Med Wom Assoc. 2000; 55: 191-194
        • Honkanen H.
        • von Hertzen H.
        Users' perspectives on medical abortion in Finland.
        Contraception. 2002; 65: 419-423
        • Winikoff B.
        Acceptabilty of medical abortion in early pregnancy.
        Fam Plann Perspect. 1995; 27: 142-148
        • Suhonen S.
        • Heikinheimo O.
        • Tikka M.
        • Haukkamaa M.
        The learning curve is rapid in medical termination of pregnancy���first-year results from the Helsinki area.
        Contraception. 2003; 67: 223-227
        • Kahn J.G.
        • Becker B.J.
        • MacIsaa L.
        • et al.
        The efficacy of medical abortion: a meta-analysis.
        Contraception. 2000; 61: 29-40
        • Reeves M.F.
        • Kudva A.
        • Creinin M.D.
        Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac.
        Contraception. 2008; 78: 332-335
        • Orioli I.M.
        • Castilla E.E.
        Epidemiological assessment of misoprostol teratogenicity.
        Br J Obstet Gynaecol. 2000; 107: 519-523
        • Gary M.M.
        • Harrison D.J.
        Analysis of severe adverse events related to the use of mifepristone as an abortifacient.
        Ann Pharmacother. 2006; 40: 784
        • Allen R.H.
        • Westhoff C.
        • De Nonno L.
        • Fielding S.L.
        • Schaff E.A.
        Curettage after mifepristone-induced abortion: frequency, timing, and indications.
        Obstet Gynecol. 2001; 98: 101-106
        • Centers for Disease Control and Prevention (CDC)
        Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol ��� United States and Canada, 2001���2005.
        MMWR. 2005; 54: 724
        • Fischer M.
        • Bhatnagar J.
        • Guarner J.
        • et al.
        Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.
        NEJM. 2005; 353: 2352-2360
        • Cohen A.L.
        • Bhatnagar J.
        • Reagan S.
        • et al.
        Toxic shock associated with Clostridium sordellii and Clostidium perfringens after medical and spontaneous abortion.
        Obst Gynecol. 2007; 110: 1027-1033
        • Sawaya G.F.
        • Grady D.
        • Kerlikowske K.
        • Grimes D.A.
        Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis.
        Obstet Gynecol. 1996; 87: 884-890
        • Baulieu E.E.
        Deaths from Clostridium sordellii after medical abortion.
        NEJM. 2006; 354: 1645-1647
      11. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111341.htm [accessed September 20, 2009].

        • Fjerstad M.
        • Trussell J.
        • Sivin I.
        • Lichtenberg E.S.
        • Cullins V.
        Rates of serious infection after changes in regimens for medical abortion.
        NEJM. 2009; 361: 145-151
        • Finer L.B.
        • Henshaw S.K.
        Abortion incidence and services in the United States in 2000.
        Perspect Sexual Reprod Health. 2003; 35: 6-15
        • Faucher P.
        • Baunot N.
        • Madelenat P.
        The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients.
        Gynecol Obstet Fertil. 2005; 33 ([French]): 220-227
      12. Gemperli MP, Stewart FH, Phillips KA, Sakowski J, Van Bebber S, Bergthold L. A qualitative study of insurers' coverage for mifepristone-induced abortion. Managed Care Interface 2005;18:26--30, 32.

        • Hwang A.C.
        • Koyama A.
        • Taylor D.
        • Henderson J.T.
        • Miller S.
        Advanced practice clinicians' interest in providing medical abortion: results of a California survey.
        Perspect Sex Reprod Health. 2005; 37: 92-97
        • Leeman L.
        • Asaria S.
        • Espey E.
        • Ogburn J.
        • Gopman S.
        • Barnett S.
        Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion?.
        Contraception. 2007; 76: 96-100
        • Schwarz E.B.
        • Luetkemeyer A.
        • Foster D.G.
        • Weitz T.A.
        • Lindes D.
        • Stewart F.H.
        Willing and able? Provision of medication for abortion by future internists.
        Womens Health Issues. 2005; 15: 39-44
        • Gomperts R.J.
        • Jelinska K.
        • Davies S.
        • Gemzell-Danielsson K.
        • Kleiverda G.
        Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
        BJOG. 2008; 115: 1171-1175
        • Cheng L.
        • Gulmezoglu A.M.
        • Piaggio G.
        • Ezcurra E.
        • Van Look P.F.
        Interventions for emergency contraception.
        Cochrane Database Syst Rev. 2008; : CD001324
        • Bracken H.
        • Ngoc N.T.
        • Schaff E.
        • et al.
        Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
        Obstet Gynecol. 2007; 109: 895-901
        • Hamoda H.
        • Ashok P.W.
        • Flett G.M.
        • Templeton A.
        A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation.
        BJOG. 2005; 118: 1102-1108
        • Hamoda H.
        • Ashok P.W.
        • Flett G.M.
        • Templeton A.
        A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation.
        Hum Reprod. 2005; 20: 2348-2354
        • Bartley J.
        • Baird D.T.
        A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy.
        BJOG. 2002; 109: 1290-1294
        • Coughlin L.B.
        • Roberts D.
        • Haddad N.G.
        • Long A.
        Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective?.
        J Obstet Gynaecol. 2004; 24: 69-71
        • Wagaarachchi P.T.
        • Ashok P.W.
        • Narvekar N.N.
        • Smith N.C.
        • Templeton A.
        Medical management of late intrauterine death using a combination of mifepristone and misoprostol.
        BJOG. 2002; 109: 443-447
        • Cohn M.
        • Stewart P.
        Pretreatment of the primigravid uterine cervix with mifepristone 30 h prior to termination of pregnancy: a double-blind study.
        Br J Obstet Gynaecol. 1991; 98: 778-782
        • World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation
        Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial.
        Hum Reprod. 1995; 10: 308-314
        • DeBattista C.
        • Belanoff J.
        • Glass S.
        • et al.
        Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
        Biol Psych. 2006; 60: 1343-1349
        • Johanssen S.
        • Allolio B.
        Mifepristone (RU 486) in Cushing's syndrome.
        Eur J Endocrinol. 2007; 157: 561-569
        • Schafer E.A.
        • Venkatachari N.J.
        • Ayyavoo V.
        Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
        Antiviral Res. 2006; 72: 224-232
        • Eisinger S.H.
        • Bonfiglio T.
        • Fiscella K.
        • et al.
        Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas.
        J Minimally Invasive Gynecol. 2005; 12: 227-233
        • Spitz I.M.
        • Grunberg S.M.
        • Chabbert-Buffet N.
        • et al.
        Management of patients receiving long-term treatment with mifepristone.
        Fertil Steril. 2005; 84: 1719-1726
        • Koivisto-Korander R.
        • Leminen A.
        • Heikinheimo O.
        Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma.
        Obstet Gynecol. 2007; 109: 512-514
      13. Bygdeman M, Danielsson KG, Marions L. Medical termination of early pregnancy: the Swedish experience. J Am Med Womens Assoc 2000;55(3 Suppl):195--6, 204.